Posts by Steven Chervenick
Vinorelbine Could Soon be Used to Treat Mesothelioma
Vinorelbine could be a useful second-line treatment for patients with relapsed mesothelioma. A phase II clinical trial examined vinorelbine to see how effective it is in patients who had their pleural mesothelioma progress after platinum chemotherapy treatment. Doctors believe vinorelbine could be another option for patients instead of the standard platinum-based chemotherapy. The study, which…
Read MorePleural Effusion in Mesothelioma Patients May Affect Survival
Pleural effusion may affect mesothelioma survival. Pleural effusion is a buildup of fluid around the lungs that can be caused by multiple illnesses including heart failure, kidney and liver disease, pleural mesothelioma, and other cancers. The only way to treat this condition is to drain the fluid, which makes it easier for patients to breathe.…
Read MoreA Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
Primary Outcome Measures Objective response rate (ORR) [ Time Frame: Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximatively 9 months after the last participant receive first dose. ] Objective response rate (ORR), defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR), derived based…
Read MoreAdjuvant Radiotherapy Does Not Improve Survival in Pleural Mesothelioma Patients
Adjuvant radiotherapy might not be the best treatment for mesothelioma sufferers because researchers at Duke and Stanford found that this therapy does not help patients live longer. The researchers analyzed a database of pleural mesothelioma patients at Duke and a national registry of patients. The research looked at the outcomes of patients with radiation after…
Read MoreStudy of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Primary Outcome Measures Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 28 Days ] A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by the investigator to be clinically…
Read MoreDoctors Should Use Pleurectomy Decortication Surgery Over Extrapleural Pneumonectomy Surgery
A study looking at many patients with pleural mesothelioma found that there is not enough of a survival advantage to support the use of extrapleural pneumonectomy surgery (EPP). The study was done at the MD Anderson Cancer Center at the University of Texas. EPP is the most aggressive surgery for mesothelioma and at one point…
Read MoreMesothelioma Patients with High Levels of the PD-L1 Protein Have Shorter Survival
Unfortunately for mesothelioma patients with high levels of the PD-L1 protein, they have a worse overall survival compared to patients who have lower levels. A European study looking at 200 patients wanted to see if PD-L1 and PD-1, popular targets for immunotherapy drugs, impact survival independently without immunotherapy drugs present. The researchers found that the…
Read MoreTri-Modality Therapy Triples Survival Compared to Chemotherapy and Surgery Alone
A very aggressive mesothelioma treatment is proving to be more beneficial compared to just chemotherapy and surgery alone. The more aggressive therapy utilizes multiple techniques creating a more successful treatment in certain patients. Mesothelioma treatment needs to be aggressive because it is a tough to treat and aggressive cancer. People diagnosed typically only live a…
Read MorePleurectomy/Decortication Surgery Can Improve Quality of Life, Even in Patients with Declining Lung Function
Researchers at the Hyogo College of Medicine have found that pleurectomy/decortication surgery can improve quality of life in mesothelioma patients, even if they have declining lung function. The researchers looked at 45 patients who received pleurectomy/decortication surgery between the years 2014 and 2018. After the patients received surgery, lung function tests showed that most of…
Read MoreA Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Primary Outcome Measures Number of patients with adverse events and serious adverse events [ Time Frame: 3 years ] Safety and tolerability of IAG933 Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only) [ Time Frame: 1 year ] Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933 Number of patients with dose interruptions and dose…
Read More